Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
JPMorgan Chase & Co.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $953.3B | |
|---|---|---|
| Revenue (ttm) | 190.7B | |
| Net income (ttm) | 64.5B | |
| EPS (ttm) | $23.8 | |
| Shares out | 2.7B | |
| P/E (trailing) | 14.2x | |
| P/E (forward) | 14.5x | |
| Dividend | $6.60 (1.95%) | |
| Volume | 3,608,127 | |
| Beta | 1.02 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $121.65B | $128.70B | $158.10B | $177.56B | $182.45B | +10.7% |
| Gross profit | $130.91B | $121.39B | $145.67B | $158.79B | $167.61B | +6.4% |
| Operating income | $59.56B | $46.17B | $61.61B | $75.08B | $72.60B | +5.1% |
| Net income | $48.33B | $37.68B | $49.55B | $58.47B | $57.05B | +4.2% |
| EPS (diluted) | $15.36 | $12.09 | $16.23 | $19.75 | $20.02 | +6.8% |
| EBITDA | $67.49B | $53.22B | $69.12B | $83.02B | $81.42B | +4.8% |
| R&D | — | — | — | — | — | — |
| SG&A | $38.57B | $41.64B | $46.47B | $51.36B | $54.49B | +9.0% |
Recent company headlines from major financial publishers.
This outcome assumes the earnings reset holds, growth normalizes in FY2027, and the geographic revenue mix remains broadly stable. Results near central FY2027 forecasts would support this outlook.
This outcome requires FY2027 revenue and diluted EPS near the upper ends of their forecast ranges, supported by continued repurchases. Margin erosion or rising diluted shares would disconfirm the outlook by FY2027.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.8% | $326 | $339 | $356 | $377 | $407 |
| 7.8% | $291 | $299 | $308 | $320 | $335 |
| 8.8% | $265 | $270 | $276 | $283 | $291 |
| 9.8% | $244 | $247 | $251 | $255 | $260 |
| 10.8% | $227 | $229 | $231 | $234 | $237 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
